Costs and Benefits of Influenza Vaccination and Work Productivity in a Colombian Company from the Employer's Perspective

Abstract

AbstractObjectivesThis study was designed to evaluate the effects of an employee influenza vaccination campaign, measured in terms of health and economic benefits.MethodsColombian bank employees volunteered to take part in this prospective observational study involving two groups: vaccinated and nonvaccinated. Socioeconomic and health status information, including influenza-like symptoms, sick leave, and postvaccination adverse events, were collected via questionnaires. Cost–benefit analyses were performed to determine whether the employer would save money overall by paying for the vaccination program.ResultsBetween October 2000 and May 2001, 424 vaccinated subjects and 335 nonvaccinated subjects volunteered to join the study. Cumulative incidence of influenza-like illness (ILI) was lower among vaccinated (14.6%) than nonvaccinated subjects (39.4%). Fever was the most common ILI symptom (93% of all reported ILI). Absence rates because of ILI were similar in the two groups (2.59%−2.69%). Assuming that employees with ILI who continue to work have reduced effectiveness (30%−70% of normal) the employer can save US$6.4 to US$25.8 per vaccinated employee based on labor costs alone. This saving increases to US$89.3 to US$237.8 when operating income is also considered. Sensitivity analyses indicate that the vaccination program will be cost saving for vaccination coverage above 20% and ILI rates above 10%.ConclusionsAmong the studied volunteers, ILI has significant impact on work productivity in terms of indirect costs. Implementing an influenza vaccination program would reduce the burden of ILI and save substantial amounts of money for the company